Orexin-A
Orexin-A (Hypocretin-1)
Orexin-A (Hypocretin-1) is a 33-amino acid neuropeptide produced in the lateral hypothalamus that plays a critical role in regulating wakefulness, arousal, appetite, and energy homeostasis. It is primarily researched for its ability to promote wakefulness and counteract narcolepsy-like states, with emerging interest in cognitive enhancement and motivation. Deficiency of orexin signaling is the primary pathological mechanism underlying narcolepsy type 1.
Mechanism of Action
Orexin-A binds to both OX1R and OX2R G-protein coupled receptors (with higher affinity for OX1R compared to Orexin-B), activating downstream signaling cascades that promote noradrenergic, dopaminergic, histaminergic, and serotonergic neurotransmission to sustain wakefulness and arousal. It stabilizes sleep-wake transitions by reinforcing the 'flip-flop' switch in the hypothalamus, preventing inappropriate transitions into REM sleep. Additionally, OX1R activation in the prefrontal cortex and mesolimbic pathways is associated with enhanced attention, motivation, and reward-seeking behavior.
Evidence by Health Goal(18 goals)
Dosing Protocols
Upon waking or 30 minutes before a cognitive task requiring sustained attention
Cycle: 5 days on, 2 days off
Intranasal delivery is the most practical non-invasive route for CNS delivery, bypassing the blood-brain barrier via olfactory and trigeminal pathways. Dissolved in sterile saline or PBS at 1-2mg/mL. Onset within 15-30 minutes. Research-grade use only; no approved human formulation exists.
Morning administration, on empty stomach preferred
Cycle: 4 weeks on, 2 weeks off
Intracerebroventricular (ICV) administration is used in research settings and is not feasible outside of clinical/surgical contexts. Peripheral IV/subcutaneous injection yields poor CNS penetration due to rapid degradation and poor BBB crossing. Subcutaneous dosing used experimentally at higher doses (100-500mcg) with uncertain CNS bioavailability.
Safety & Side Effects
Orexin-A has no approved therapeutic formulation for human self-administration, and all human data comes from experimental or early clinical research contexts; long-term safety in self-administered settings is entirely unknown. While it is not a controlled substance, it carries meaningful cardiovascular and neuropsychiatric risks, and receptor desensitization or dysregulation with chronic use is a legitimate concern.
Possible Side Effects
- !Increased heart rate and mild hypertension due to sympathomimetic activation
- !Anxiety or heightened stress response via OX1R-mediated CRF pathway activation
- !Appetite stimulation and potential compulsive food-seeking behavior
- !Nasal irritation or mucosal dryness with intranasal formulations
- !Insomnia or disrupted sleep architecture if dosed too late in the day
- !Headache, particularly with initial use or higher doses
- !Potential rebound hypersomnolence following discontinuation after prolonged use
Interactions
- -May potentiate stimulant effects of amphetamines, modafinil, or caffeine — increasing cardiovascular strain and anxiety risk
- -May antagonize or reduce efficacy of suvorexant, lemborexant, and other orexin receptor antagonists used for sleep
- -Additive sympathomimetic effects possible with yohimbine or other alpha-2 adrenergic antagonists
- -May amplify appetite and reward-seeking behaviors when combined with ghrelin-stimulating compounds or MK-677
- -Potential interaction with SSRIs/SNRIs via shared modulation of serotonergic and noradrenergic tone — unpredictable CNS effects
Cost & Where to Buy
Research-grade Orexin-A peptide from reputable vendors (e.g., Bachem, Peptide Sciences, or similar) typically runs $50-150 per 500mcg vial; monthly cost depends heavily on dose and frequency. Purity certification (HPLC >98%) is essential and affects price significantly.
Search on Amazon